Dr. KinyasHair Clinic · IstanbulLibrary ←
Science and Research Centre / Hair Loss and Treatments

Dr. Kinyas Hair Clinic · Science and Research Centre

Hair Mesotherapy: Ask About Contents and Evidence Before the Method Name

Mesotherapy is not one medicine or standard formula; it describes a delivery approach. Benefits and safety cannot be assessed without exact contents, intended purpose and supporting research.

Different treatments share one heading

Vitamin, peptide, drug and other preparations cannot be combined as one research result. Concentration, vehicle and route matter alongside ingredient identity. Oral-drug evidence does not validate scalp injection of the same drug. [1] (principle of evidence transfer)

Ask for exact product identity, rationale and alternatives. Nourishes hair does not explain a measurable goal for your diagnosis. Proposed treatment needs a clear target and follow-up plan.

What did the 2026 systematic review find?

The review published in 2026, searching through July 2025, found 30 eligible publications: only seven interventional; the rest observational or descriptive. Possible cosmetic benefits were reported across different preparations, but small groups and short follow-up were important limitations. [1]

This does not establish all mixtures as proven or routinely necessary. Numerous publications do not equal numerous strong randomised trials. Findings should not become one universal success percentage.

Separating results and interpretation in a small controlled study

An eight-person comparison of dutasteride microinfusion with saline found no statistically significant between-group clinical difference, although self-assessments were positive. A favourable conclusion cannot turn this sample into strong superiority evidence. [2]

Satisfaction and blinded photographic ratings differ. If both groups undergo needling, the active contribution needs careful separation. Uncontrolled before/after photographs cannot isolate a drug or mixture’s effect.

Can hair loss occur at injection sites?

A 2026 series of three women describes persistent patchy loss after dutasteride mesotherapy, with both scarring and nonscarring findings and incomplete regrowth in some cases. This is a safety signal. [3]

Three cases cannot estimate population risk, and mechanisms may differ. They should not be dismissed as temporary shock loss. New patches, increasing pain or inflammation at injection sites need re-examination. [3]

Why mixture, vehicle and sterile preparation matter

Attributing unexplained responses solely to the ingredient may mislead. Mechanical injury, vehicle effects, inflammation or infection are possible explanations, not established mechanisms in every case. Product and procedure records help assessment. [3]

An undisclosed mixture should not be presented on the same evidence level as an established drug. No home injections or self-mixing are advised. With unhealed transplant sites, timing needs medical assessment; this page sets no standard session schedule.

Which questions should follow-up answer?

Record diagnosis, contents, concurrent therapies and photographs. Assess predefined goals, not only whether patients feel better. Starting several treatments together makes attribution to one component difficult. [1], [2] (clinical follow-up recommendation)

Costs, sessions, alternatives and expected contribution should be understandable. If discussed with Dr. Kinyas, ask why it suits you and how declining changes the plan. No routine mixture use or universal necessity is verified here.

References and access limitations

This article is based on a targeted review of sources; it is not an original systematic review.

  1. Beer J et al. Injectable Therapy for Androgenetic Alopecia: A Systematic Review. Dermatol Surg. 2026;52:659–665. DOI: 10.1097/DSS.0000000000004999.

    Systematic review; abstract. 30 publications: seven interventional, 11 observational, 12 descriptive. Full quality/conflict tables not read. Search July 2025; later studies not automatically included.

  2. Gasques L et al. Dutasteride Infusion in Male AGA Using a Novel Drug Delivery Technique: MMP. Skin Appendage Disord. 2026;12:12–16; online 8 July 2025. DOI: 10.1159/000546871.

    Controlled study; abstract. Eight men; no significant clinical between-group difference. Assessment based on the published abstract. One author on journal editorial board, others report no conflicts. Microinfusion is not identical to all mesotherapy.

  3. Nogueira CM, Osório F. Persistent Alopecic Patches Following Dutasteride Mesotherapy for Female AGA: A Case Series. J Drugs Dermatol. 2026;25:951–955. DOI: 10.36849/JDD.9712.

    Three-case series; abstract. Cannot calculate incidence or causality across all procedures. Persistent-loss signal retained; full text of all cases not read.

← Back to section
WhatsApp
DR. KINYAS HAIR CLINIC

Quick Contact

Leave your details and we will contact you through your preferred channel.

How should we contact you?

Dr. Kinyas Hair Clinic uses your details to respond to your request and contact you.